Clinical trials: T-lymphocytes
CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL)
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.
- Trial name
- NCT06935136
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer
Non-Viral TCR Gene Therapy
Background: A person s white blood cells can be modified in a lab to recognize certain changes in their tumor. Many of these cells are collected from the person, modified, then given back to the person.
- Conditions
- Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers
- Trial name
- NCT04102436
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer, Male Breast Cancer
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
RATIONALE : Laboratory-treated T cells may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01219907
- Testing
- HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells
- Where
- United States
- Sponsor
- University of Washington
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
The COVID-19 pandemic is a global emergency threatening to take millions of lives in the United States and around the world. There is no current vaccine strategy against COVID-19 infection caused by a novel coronavirus named…
- Trial name
- NCT04397900
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- TScan Therapeutics, Inc.
Yellow Fever (Healthy Volunteers), Biopsy/Methods
Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants
In The main GeKoSkimm trial (= A randomized controlled trial to compare the immunogenicity and skin imprinting of intradermal, subcutaneous and intramuscular yellow fever vaccination) the investigators try to understand whether…
- Trial name
- NCT07636551
- Testing
- Skin punch biopsy, Blood samples
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV-1-infection, AIDS
Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes
This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.
- Trial name
- NCT04770701
- Testing
- Ahah Drug
- Where
- Vietnam
- Sponsor
- Trieu, Nguyen Thi, M.D.
Ovarian Cancer Recurrent, Ovarian Cancer
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101.
- Conditions
- Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
- Trial name
- NCT07030907
- Testing
- OPB-101
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Outpace Bio, Inc.
Neoplasms
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
- Trial name
- NCT05993299
- Testing
- Letetresgene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 7 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Lymphoma, B-Cell, Relapse/Recurrence
Dual Target CAR-T Cells in B-cell Lymphoma
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .
- Conditions
- Lymphoma, B-Cell, Relapse/Recurrence, Refractory Lymphoma, Dual-target CAR-T Cells
- Trial name
- CAR-T (NCT04723914)
- Testing
- dual target CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- YuLi
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Moderate COVID-19-infection
Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
Monocentric open phase I (dose escalation component), followed by a multi-center, randomized, phase II component benchmarking IMP+SoC against SoC
- Trial name
- ACT-COVID-19 (NCT04762186)
- Testing
- human SARS-CoV 2 specific T lymphocytes
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Universitätsklinikum Köln
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Lymphoma
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in Japanese pts.
- Trial name
- NCT00771472
- Testing
- vorinostat
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
NK T-Cell Lymphoma
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens.
- Trial name
- NCT07457177
- Testing
- Golidocitinib + Pegaspargase + Anti-PD-1 mAb
- Volunteers
- 40 people
- Sponsor
- LIANG WANG
Lupus Nephritis, Systemic Lupus Erythematosus
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 for treatment of participants with lupus nephritis (LN) following lymphodepletion (LD) and in participants with extrarenal systemic lupus…
- Trial name
- NCT06429800
- Testing
- ATA3219
- Where
- United States
- Sponsor
- Atara Biotherapeutics
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Transplant Failure
T-lymphocytes CD8+/HLA-DR+ and Acute Rejection After Lung Transplantation
The objectives of the study is to identify associations between acute rejection and the increase of T (CD4/CD8) and B circulating lymphocytes expressing specific markers of activation and differentiation (HLA-DR, CD25, CD38…
- Trial name
- NCT03587493
- Testing
- BLOOD SAMPLE ANALYSIS
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Leukemia
A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia.
- Trial name
- PLAT-04 (NCT03244306)
- Testing
- Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Seattle Children's Hospital
Relapse Multiple Myeloma
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.
- Trial name
- NCT07359014
- Testing
- Dual CD19/BCMA CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.